Market Outlook 2021 The road back to normal

Market outlook 2021: Evan Brown, head of macro asset allocation at UBS Asset Management told investors there’s more positive news around vaccine announcements and this would boost global GDP next year

27 Nov 2020

We just keep getting vaccine announcements that are extraordinarily positive … vaccines that are showing efficacy above 90%, much higher than expectation.

They are set to roll out over the coming weeks .. broadly to populations around the world. Some countries could reach herd immunity as soon as mid-2021 and that can lead to a significant rebound in the global economy next year, perhaps as much as 6% global GDP growth in 2021

Evan Brown, Head of Macro Asset Allocation

How will markets price in the near-term negative news (of increased COVID-19 cases in the West) versus the medium-term positive news (of vaccine development)?

Right now, the vaccine story is winning, but into year end or, early next year, there’s going to be a little bit more 2-way a price action that we're seeing here …

"When we do get dips in the more cyclical sectors … those are dips to be bought and we definitely do like rotating into the more cyclical areas of the markets right now."

What does the Biden administration mean for US/China relation?

There will continue to be strategic competition between the two countries, focused in particular on technology.

All that said, the areas of focus, I think, are going to shift somewhat with the Biden administration. Biden is not a tariff man like President Trump calls himself.

"We do think he will de-emphasized trade policy and tariffs, to the point where … actually tariffs begins do get removed somewhat, and as part of a partial reset in relations between the two countries. That would be a very helpful tailwind for the global economy and we see it as a good environment for global credit, particularly in Asia"

Chinese bonds a stand-out in Asian credit

Evan Brown and team has put together "Market Outlook 2021 - The Road Back to Normal" which also discussed the challenges for income generation and attractiveness of emerging markets.

Extracts of the report below.

The challenge for income generation

We believe that the overall macro environment is highly supportive of risk assets, and we have a bias towards procyclical relative value positions. The economic recovery is poised to continue and become more self-sustaining as medical innovations allow for the normalization of private-sector activity.

Real interest rates are negative across advanced economies, and are likely to stay that way through 2021 and beyond. We believe a less aggressive outlook for US fiscal stimulus limits the prospect of a sudden, significant rise in Treasury yields that would have spillovers across international markets. Investors will have to work harder to generate yield.

The appeal of opportunities in multi-asset hedge funds and alternative assets could increase in this low-yield-for-longer environment. Within the publicly traded universe, the progression of the global economic expansion coupled with the low level of yields on developed-market sovereign debt should likely push investors up the risk spectrum. In our view, this makes emerging market dollar-denominated debt, including Chinese government bonds, particularly compelling.

Attractive yield pick-up available in Chinese bonds, dollar-denominated EM debt

Source: UBS Asset Management, Bloomberg. Data as of 10 November 2020.

This chart tracks the JPMorgan Emerging Market Bond Index (EMBI) Global Spread and the China 10-year bond yield from 2016 through November 10, 2020.  

US election impact

The results of the US election provide increased clarity on the economic outlook. President-elect Joe Biden is likely to take office with a Republican Senate. This combination should provide the US economy with adequate additional fiscal support, though not as much as would have been the case in the event of a united Democrat government. In addition, the likelihood of higher taxes has lessened considerably, removing one potential headwind to US earnings growth.

In our view, this election outcome will help foster sustained US dollar weakness, with the protectionism premium embedded in the world’s reserve currency ebbing in light of this change in leadership. We expect the Treasury curve to steepen over time as the expansion makes further headway.

But the potential for ongoing, substantial fiscal stimulus stateside has diminished materially, reducing the odds of a disorderly rise in bond yields that could foster dollar strength. Linked to this outlook for a softer US dollar, the across-the-board outperformance of emerging market assets is our highest conviction view, which is bolstered by the election results.

Economic recovery conducive to outperformance of emerging markets

The broad-based economic recovery is conducive to the outperformance of emerging markets. So too is the relative status of China’s economic comeback, which is in a more advanced phase than any other nation. The resilience in the world’s engine of production and strong credit impulse may continue to bolster global activity, as long as growth in total social financing, imports, and inventories does not moderate too briskly. In our view, this positive influence is a boon for the global market outlook in general, and for emerging markets as well as other procyclical assets in particular.

Beyond the aforementioned attractiveness of dollar-denominated debt in light of current spreads, we also favor emerging market currencies, which have outsized catch-up potential relative to other procyclical trades.

Asset allocation 2021

The Asset class attractiveness chart shows the views of our Asset Allocation team on overall asset class attractiveness, as well as the relative attractiveness within equities, fixed income and currencies, as of 6 November 2020.

1 Source: UBS Asset Management’s Investment Solutions Macro Asset Allocation Strategy team as at 6 November 2020. Views are provided on the basis of a 3–12 month investment horizon, are not necessarily reflective of actual portfolio positioning and are subject to change.

Download our full "Market Outlook 2021 - The Road Back to Normal"

Market outlook 2021

Asset allocation members

Evan Brown

Head of Macro Asset Allocation Strategy

Ryan Primmer

Head of Investment Solutions

Lucas Kawa

Asset Allocation

Subscribe now

Perspectives matter. Tune in to our insights.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.